Listen

Add to my selection

TRANSLARNA (ataluren)

Medicine - Posted on Nov 07 2024

Active substance (DCI)

ataluren

history (4)

10/23/24

TRANSLARNA (ataluren) - Duchenne muscular dystrophy

Summary of opinion Unfavourable opinion for reimbursement in “the treatment of Duchenne muscular dystrophy resulting from a ...

CAV :
54321

icône flèche
10/23/19

TRANSLARNA (ataluren)

L’essentiel Avis favorable au remboursement dans le traitement de la dystrophie musculaire de Duchenne, résultant d’une muta...

CAV :
54321

icône flèche
7/5/17

TRANSLARNA (ataluren), RNA interference agent

No clinical benefit demonstrated in the treatment of Duchenne muscular dystrophy, resulting from a nonsense mutation in the ...

CAV :
54321

icône flèche
1/21/15

TRANSLARNA (ataluren), RNA interference agent

Minor improvement in the management of Duchenne muscular dystrophy TRANSLARNA has Marketing Authorisation in the treatment o...

CAV :
54321

icône flèche

Technical information

ATC code

M09AX03

Manufacturer

PTC THERAPEUTICS INTERNATIONAL LTD

Presentation

TRANSLARNA 125 mg, granulés pour suspension buvable (code CIS : 67503464)
30 sachet(s) aluminium (CIP : 34009 279 591 4 1)

TRANSLARNA 250 mg, granulés pour suspension buvable (code CIS : 65945882)
30 sachet(s) aluminium (CIP : 34009 279 592 0 2)

TRANSLARNA 1000 mg, granulés pour suspension buvable (code CIS : 68469328)
30 sachet(s) aluminium (CIP : 34009 279 593 7 0)

All our publications

Congenital, genetic and rare diseases

Muscular diseases

Neuromuscular diseases